Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation

about

Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation

Item

http://www.wikidata.org/entity/Q56764236

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2017

@uk

name

Whole body metabolic tumor vol ...... irmed with external validation

@en

Whole body metabolic tumor vol ...... irmed with external validation

@nl

type

Item

label

Whole body metabolic tumor vol ...... irmed with external validation

@en

Whole body metabolic tumor vol ...... irmed with external validation

@nl

prefLabel

Whole body metabolic tumor vol ...... irmed with external validation

@en

Whole body metabolic tumor vol ...... irmed with external validation

@nl

P1476

Whole body metabolic tumor vol ...... irmed with external validation

@en

P2093

Brittany Z Dashevsky

http://www.w3.org/2001/XMLSchema#string

Chenpeng Zhang

http://www.w3.org/2001/XMLSchema#string

Cindy Yuan

http://www.w3.org/2001/XMLSchema#string

Feng-Ming Spring Kong

http://www.w3.org/2001/XMLSchema#string

Haiyan Liu

http://www.w3.org/2001/XMLSchema#string

Li Yan

http://www.w3.org/2001/XMLSchema#string

Lingyun Xiong

http://www.w3.org/2001/XMLSchema#string

Yongmei Liu

http://www.w3.org/2001/XMLSchema#string

P2860

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer

Cancer statistics, 2016

Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer.

Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.

Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer.

Stage-adjusted lung cancer survival does not differ between low-income Blacks and Whites.

Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.

Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S41824-017-0013-Z

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yonglin Pu

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29782599

http://www.w3.org/2001/XMLSchema#string

P932

5954780

http://www.w3.org/2001/XMLSchema#string